The DanShock trial (NCT01633502) assessed the efficacy of the Impella CP ventricular assist device in reducing mortality following myocardial infarction (MI). The Impella CP is a catheter-based axial flow pump that directly channels blood from the left ventricle into the circulation, delivering 3.5L/min (approximately 75% of normal cardiac output). Investigators randomized 360 patients to receive either a microaxial flow pump plus standard of care (SOC) (n=179) or SOC alone (n=176). The primary endpoint was all-cause mortality at 180 days. In the microaxial-flow-pump + SOC group, 82 patients (45.8%) died from any cause, compared to 103 patients (58.5%) in the SOC alone group, yielding a hazard ratio (HR) of 0.74 (confidence interval [CI] 0.55 to 0.99; P=0.04).
For more cardiology research news join our newsletter or follow us on Twitter, Facebook, LinkedIn or Instagram.
